A phase II study of pembrolizumab plus carboplatin in BRCA-related metastatic breast cancer (PEMBRACA).
ESMO Open
; 8(2): 101207, 2023 04.
Article
in En
| MEDLINE
| ID: mdl-37028000
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
BRCA1 Protein
/
Triple Negative Breast Neoplasms
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
ESMO Open
Year:
2023
Document type:
Article